Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study of Live Biotherapeutic Product (LBP) MARCO (Microbiota Augmentation to Reestablish Commensal Organisms) Combined With Ruxolitinibfor Patients With Steroid Refractory or Intolerant Gastrointestinal Acute Graft-versus-Host Disease (aGVHD) After Allogeneic Cell Transplantation (Allo-HCT) (MARCO-GVHD Trial)

NCT07913672 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07913672 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study of Live Biotherapeutic Product (LBP) MARCO (Microbiota Augmentation to Reestablish Commensal Organisms) Combined With Ruxolitinibfor Patients With Steroid Refractory or Intolerant Gastrointestinal Acute Graft-versus-Host Disease (aGVHD) After Allogeneic Cell Transplantation (Allo-HCT) (MARCO-GVHD Trial)
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Overall status
Recruiting
Start date
October 27, 2026
Completion date
October 27, 2028
Enrollment
16 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

transplant failure or rejection of bone marrow (graft vs host disease, gvhd)

Arms

As registered; 3 arms.

  • Consortia A ExperimentalLBP- MARCO, Ruxolitinib

    Participants in Cohort 1 will receive LBP-MARCO with the same combination of 7 specific types of bacteria.

  • Consortia B ExperimentalLBP- MARCO, Ruxolitinib

    If the bacteria do not grow or produce enough metabolites, the next group of participants (Cohort 2) will get LBP-MARCO with a different combination of bacteria.

  • Consortia C ExperimentalLBP- MARCO, Ruxolitinib

    If that combination does not grow in participants' guts, the next group of participants (Cohort 3) will get LBP-MARCO with a different combination of the bacteria.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • incidence and severity of SAEs up to 100 days

    Grade 2-4 infections by CTCAE v6 either clinically or microbiologically will be assessed throughout the study until day +100. Causality and relationship with aGVHD, LBP-MARCO, and ruxolitinib will be determined.

Patents and exclusivity

By drug, as the FDA Orange Book declares its patents.

  • Ruxolitinib 34 Orange Book patentsPatent cliff May 5, 2041 (Orange Book patent)
    • US 11602536; expires May 5, 2041; assignee Incyte Corp
    • US 11510923; expires September 4, 2040; assignee Incyte Corp
    • US 11590137; expires September 4, 2040; assignee Incyte Corp
    • US 12589096; expires September 4, 2040; assignee not stated
    • US 12233067; expires July 28, 2040; assignee Incyte Corp
    • +29 more patents

Lead sponsor's other trials

Memorial Sloan Kettering Cancer Center, most recent start first.

Similar trials

Same condition (Graft vs Host Disease) and phase, most recent start first.